Parasitologic Assessment of Two-Dose and Monthly Intermittent Preventive Treatment of Malaria during Pregnancy with Sulphadoxine-Pyrimethamine (IPTP-SP) in Lagos, Nigeria by Agomo, Chimere O. et al.
SAGE-Hindawi Access to Research
Malaria Research and Treatment
Volume 2011, Article ID 932895, 6 pages
doi:10.4061/2011/932895
Research Article
Parasitologic Assessment of Two-Dose andMonthly Intermittent
PreventiveTreatmentofMalariaduringPregnancywith
Sulphadoxine-Pyrimethamine(IPTP-SP) in Lagos, Nigeria
Chimere O. Agomo,1,2 WellingtonA. Oyibo,1 andFunkeOdukoya-Maije3
1Tropical Diseases Laboratory, Department of Medical Microbiology and Parasitology, College of Medicine, University of Lagos,
Lagos, Nigeria
2Malaria Research Laboratory, Department of Biochemistry, Nigerian Institute of Medical Research, P.M.B 2013 Yaba, Lagos, Nigeria
3Department of Obstetrics and Gynaecology, Ajeromi General Hospital, Ajegunle, Lagos, Nigeria
Correspondence should be addressed to Wellington A. Oyibo, waoyibo@gmail.com
Received 25 May 2011; Revised 10 August 2011; Accepted 30 August 2011
Academic Editor: Mats Wahlgren
Copyright © 2011 Chimere O. Agomo et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Intermittent preventive treatment of malaria with sulphadoxine-pyrimethamine (IPTP-SP) is a key strategy in the control of
malaria in pregnancy. However, reports of increasing level of resistance to SP using nonpregnant populations have made it
imperative for the continuous monitoring of the eﬃcacy of SP in pregnant women. This study assessed using microscopy, monthly
dosingandthestandardtwo-doseregimenamong259pregnantwomenattendingantenatalclinicsinLagos,Nigeriathatconsented
122 in the two-dose arm (ArmA) and 137 in the monthly dose arm (ArmB). Baseline parasitaemia in the two groups was 5 (4.1%)
and 3 (2.2%) in Arms A and B, respectively. Few of the women developed parasitaemia after the initial SP dose in Arms A 4 (3.3%)
and B 2 (1.5%). However, none of the women had malaria infection after the second dose in both Arms. Although IPTP-SP is
suggestive of protecting the women from malaria infection, there was no signiﬁcant diﬀerence observed between the two dosing
schemes.
1.Introduction
An estimated 25–30 million women become pregnant annu-
ally in malaria-endemic areas of Africa, most of them living
in areas of stable malaria transmission [1]. The immunosup-
pression associated with pregnancy and the absence of spe-
ciﬁc immunity to the unique subset of parasites (VAR2CSA)
that sequester in the placenta, especially in primigravidae,
are the reasons for the increased susceptibility of pregnant
women to malaria infection [2, 3]. However, the antidisease
immunity acquired prior to pregnancy keeps the infection
asymptomatic in presentation. However, the subclinical
infection still poses a great danger to both the mother and
the foetus. The presence of parasites in the placenta can lead
to maternal anaemia (potentially responsible for maternal
d e a t hw h e ns e v e r e ) ,l o wb i r t hw e i g h t( L B W ) ,c o n g e n i t a l
malaria, premature delivery, abortion, and stillbirth [4–6].
Current strategies to control malaria in pregnancy are
the intermittent preventive treatment with sulphadoxine-
pyrimethamine (IPTp-SP), use of insecticide-treated bed
nets, and case management of malaria illness and anemia [1,
7]. IPTp-SP is the administration of two or more therapeutic
doses of SP regardless of the presence of malarial infection,
at an interval of at least four weeks, starting in the second
trimester of pregnancy (after quickening). The ﬁrst SP dose
is administered in the second trimester after quickening and
the second dose of SP in the third trimester to ensure that the
placenta is cleared of malaria parasites at the time of rapid
foetal growth [8]. Two doses of SP are recommended for
HIV-negative pregnant women while HIV-positive women
a r et or e c e i v e3d o s e so fS P[ 7].
PriortotheintroductionofIPTp-SP,antimalariachemo-
prophylaxis during pregnancy was based on administration
of weekly pyrimethamine or chloroquine (CQ) [9]. The2 Malaria Research and Treatment
eﬀectiveness of weekly chemoprophylaxis with CQ and
pyrimethamine was marred by poor compliance and emer-
gence of P. falciparum strains that are resistant to these drugs
[10,11].Apartfromlowercostandhighercompliance,IPTp-
SP is signiﬁcantly better than CQ at reducing the rate of
placental infection, anaemia, and low birth weight [12–14].
Weekly prophylaxis with SP is not recommended because of
thehighlikelihoodoffatalreactionssuchasSteven-Johnson’s
syndrome resulting from frequent administration of SP [15].
Sulphadoxine-pyrimethamine is an antifolate drug. Folic
acid is needed by the malaria parasites for the biosynthesis of
purines and pyrimidines needed for DNA synthesis and cell
multiplication. The combination of pyrimethamine and sul-
phadoxine thus oﬀers a two-step synergistic inhibition of the
bifunctional enzyme dihydrofolate reductase-thymidylate
synthase (DHFR-TS) and dihydropteroate synthase (DHPS)
in the folate synthetic pathway. This leads to a failure of
nuclear division and subsequent cell death [16, 17].
The eﬃcacy of IPTpSP results from intermittent clear-
ance of parasitaemia and mostly through posttreatment pro-
phylaxis, provided that eﬀective antiparasitic concentrations
ofthedrugweremaintainedduringtheentiredosinginterval
[8]. Sulphadoxine-pyrimethamine is well absorbed after oral
administration, achieving peak plasma levels within 2 to
8h, have >90% bioavailability, and are 85–90% protein
bound [18]. Sulphadoxine is metabolized via glucuronida-
tion and excreted primarily in urine. Pyrimethamine is
metabolized to several metabolic products, and ∼15–30%
is excreted unchanged in urine [19]. The mean terminal
eliminationhalf-livesare200and100hforsulphadoxineand
pyrimethamine, respectively, in healthy nonpregnant adults
[20, 21].
IPTp-SPeﬃcacydependsonthemaintenanceofantipar-
asitic concentrations over the dosing intervals. SP has a good
safety proﬁle after the ﬁrst trimester, has not been associated
with adverse eﬀects on the foetus, and is well tolerated by
mothers. The estimated risk of severe adverse reactions to
IPTp-SP(monthlyorlessoften)is0–6.3%[22].Fataladverse
reactions to SP were estimated to be 0.11 deaths/100,000
SP exposures [23, 24]. The administration of SP in the
ﬁrst trimester is not advised because of potential teratogenic
eﬀect on the foetus [7].
SomereportssuggestthatmonthlyIPTp-SPmaybemore
appropriate in areas that are hyper- and holoendemic for
malaria [25, 26]. Parasitological failure rate of 24.4% on day
14 of SP has been reported among children aged 6 months
to ﬁve years with acute uncomplicated malaria in South-
west Nigeria [27]. It is therefore important to determine the
parasitologic outcome with the 2-dose regimen in protecting
pregnant women from malaria in Lagos (a holoendemic
area), especially in the context where data on parasitologic
monitoring of IPTp-SP in Nigeria is unavailable. A malaria
prevalence rate of 7.7% among pregnant women attending
these health facilities had been reported previously [28].
This paper reports the outcome of parasitologic assess-
ment of the standard 2-dose regimen and the monthly
dose of IPTp-SP in preventing malaria parasitaemia during
pregnancy in Lagos, Nigeria, in the light of documented SP
resistance reports in children and the adult population.
2.MaterialsandMethods
The ﬁeld study was conducted in Lagos, Nigeria, speciﬁ-
cally at the Ajeromi General Hospital, Ajegunle, a govern-
ment secondary health facility and the St. Kizito Primary
Healthcare Center, Lekki, a non-for-proﬁt primary health
facility. Routine antenatal care in these facilities included:
monitoring of body weight, blood pressure, haemoglobin
level, and urinalysis. Health talks were given at each clinic
day. The women received haematinics Folic acid tablets as
routine care in pregnancy. HIV counseling and testing along
with screening for sexually transmitted diseases are part of
routinepreconditionsforreceivingantenatalservicesinthese
hospitals. The laboratory studies were done at The Interna-
tionalMalariaMicroscopyTrainingCentre,TropicalDiseases
Research Laboratory, Department of Medical Microbiology
and Parasitology, College of Medicine of the University of
Lagos, Idi-Araba, Lagos, Nigeria.
The population of pregnant women in Lagos is approxi-
mately 640,000 (i.e., 4% of the total population). Assuming
a worst cure rate of 50% for SP at 95% conﬁdence interval,
precision of 10%, and a dropout rate of 10%, a minimum
sample size of 60 is needed for each arm giving a total of 120
pregnant women.
2.1. Enrolment of Study Participants. Pregnant women at-
tending the antenatal clinics (ANCs) who consented to
participate in the study were recruited at booking (ﬁrst regis-
tration, usually after 16 weeks). The study participants were
given study numbers and personal identiﬁers removed to
ensure conﬁdentiality. Access to study records was restricted.
The inclusion criteria were (a) pregnancy at second trimester
(b) no history of allergic reaction to sulphonamides, and (c)
HIV negative. The exclusion criteria were (a) positive test
forVDRL,diabetics,andhypertension(essentialorpregnan-
cyinduced) (b) severe anaemia (PCV < 20%) (c) multiple
pregnancy as determined by an ultrasound scan report and
other severe illness that could require hospitalization. The
women were given a dose of SP (1500mg sulphadoxine and
75mg pyrimethamine) in three tablets. The SP was obtained
directly from the manufacturer.
The pregnant women were randomly assigned into two
major arms: Arm A received the standard 2 doses of SP and
Arm B received monthly dose of SP. The randomization was
done by asking the women to pick up shuﬄed envelopes
containing the study arms. In addition, the laboratory staﬀs
including the microscopists were blinded to the allocations
of the patients. In Arm A, the study participants were given
a treatment dose of SP (3 tablets each containing 500mg
sulphadoxine and 25mg pyrimethamine) in the second
trimester and another treatment dose in the third trimester.
In Arm B, the participants received a treatment dose of SP
monthly. In both arms, parasitaemia were assessed monthly.
All the participants were parasitologically and clinically
monitored at each visit before delivery.
The indicators used in this study were parasite clearance,
monitoring of parasitaemia, and delivery outcome. The
parasite clearance was assessed by the proportion of women
that were parasitaemic who became aparasitaemic after theMalaria Research and Treatment 3
intake of SP. Monitoring of parasitaemia was done monthly
beforeSP administration. The delivery outcome wasassessed
by the number of live births and low birth weight babies.
Low birth weight was deﬁned as birth weight less than 2.5kg.
In addition, demographic and other information including
insecticide-treated bed nets’ use were collected through a
questionnaire that was administered.
2.2. Collection of Samples. Venous blood samples (∼2mL)
were collected from the participants at recruitment and at
each antenatal visit from their 2nd trimester. Two slides of
thin and thick ﬁlms (on the same slide) were made for each
study participant.
2.3. Followup of Study Participants. All the study participants
were monitored monthly for malaria parasitaemia. Those
that missed appointment days were contacted by phone and
appointments rescheduled within one week. Alternatively,
they were visited at home. The administration of SP was
by directly observed treatment (DOT) method. The SP was
directly obtained from the manufacturers. At each monthly
visit, routine clinical assessments for safety were conducted
onthepregnantwomenandbloodcollectedforparasitologic
and other investigations. The month of recruitment was
termed Month 0 (M0). Subsequent follow-up months were
termed M1, M2, M3, and M4. The participant that became
positive with malaria parasite during followup was treated
with oral quinine (600mg, three times daily for one week).
At delivery, placental blood samples were obtained by
making an incision on the placenta tissue (maternal surface)
and blood collected with a 2mL syringe. Infants were
weighed with a digital scale at birth.
2.4. Laboratory Methods. Thin and thick smears were pre-
pared for each participant following standard procedures for
malaria microscopy. Two competent microscopists read each
slide, and when there was discordance in reading, a third
microscopist reread the slide and served as a tie breaker.
Essentially, the discordance level for the acceptance of any
two parasite counts was set at less than 20%. The packed
cell volume (PCV) was determined using standard protocol.
Anaemia in pregnancy was deﬁned as PCV < 33% [29].
2.5. Ethical Consideration. Approvals to conduct this study
were obtained from the Research Grants and Experimenta-
tionEthics Committee,CollegeofMedicine oftheUniversity
of Lagos and the Institutional Review Board of the Nigerian
Institute of Medical Research, Lagos. Generally, the protocol
was conducted in accordance with Good Clinical Practice
(GCP), Good Clinical Laboratory Practices (GCLPs) and
indeed the tenets of the Helsinki Declaration of 1964 as
amended in 2000.
2.6. Data Analysis. The data generated from the study were
analyzed using EPIINFO 2002 statistical software (CDC,
Atlanta, GA, USA). Tests for associations and diﬀerences
were done by chi-square analysis, Fischer Exact test, and
analysis of variance where done as appropriate. P value less
than 0.05 was taken as signiﬁcant.
3. Results
A total of 259 pregnant women who were in their second
trimester were enrolled: 122 (47.1%) in Arm A (standard 2-
dose IPTp-SP) and 137 (52.9%) in Arm B (monthly IPTp-
SP). The study participants in the two arms of the study had
similar baseline characteristics (Table 1)( P>0.05).
The number of pregnant women with parasitaemia at
enrolment (M0) was 5 (4.1%) and 3 (2.2%) in Arms A
and B, respectively. The mean parasitaemia at M0 was
777.4 parasites/µL (range, 111–2,063 parasites/µL) and 691.7
parasites/µL(range,127–1,664)inArmAandB,respectively,
but reduced at M1 in both Arms to298.3 parasites/¯L (range,
149–390 parasites/µL) and cleared at M2 in Arm B. Few of
the women developed parasitaemia after the initial SP dose
in Arms A, 4 (3.3%) and B, 2 (1.5%) (P = 0.577). None of
thewomeninbothArmsofthestudydevelopedparasitaemia
after the second dose of SP (which for Arm A was from
M2). The proportion of women infected was reduced to 20%
and 0% in Arms A and B, respectively, (Figure 1). None of
the study participant developed clinical malaria during the
followup.
In a total of 12 placental blood samples collected from
women in Arm B. none (0.0%) of the samples had malaria
parasitaemia.
The result of pregnancy outcome was obtained from a
subset of 156 of the 259 women studied. The birth outcome
was assessed based on the proportion of live birth and weight
of the babies. There were a total of 149 (95.5%) live births
and 7 (4.5%) deaths recorded. Of the foetal deaths, 3 (2.9%)
were from women in monthly IPTp-SP and 4 (7.5%) from
women in the 2-Dose IPTp-SP. There was no statistical
association (P = 0.178) between the proportion of deaths
andthestudyarms.ThemeanweightofthebabieswithLBW
was 1.9±0.1kgand2.0±0.4kg (range 1.4–2.3 kg) in Arms A
and B respectively while the babies with normal birth weight
(NBW) had a mean weight of 3.3 ± 0.4kgand3.3 ± 0.4kg
in Arms A, and B, respectively. The proportion of LBW in
the monthly IPTp-SP (Arm B) (5 (5.0%)) was similar to the
standard 2-dose IPTp-SP (Arm A) (2 (4.1%)) (P = 0.581).
The age and gravidity of women whose babies died were
not signiﬁcantly associated (P = 0.907) with the study arms.
Also, the age and gravidity of women who had LBW babies
were not signiﬁcantly associated with the IPTp-SP dosing
schemes.
4. Discussion
The administration of IPTp-SP was eﬀective in protecting
4 (3.3%) in Arm A and 2 (1.5%) in Arm B of the study
participants from malaria infection and clinical malaria. A
similar ﬁnding was reported by Nyunt and colleagues [30]
where 1 of the 98 pregnant women who were on IPTp-
SP became parasitemic, none developed clinical malaria
during the period of followup and also none of the patients
tested positive for P. falciparum on assessment of placental4 Malaria Research and Treatment
Table 1: Baseline characteristics of the study participants.
Arm A Arm B
Number 122 137
Mean age (years) 26.5 ±4.22 7 .9 ±4.9
Gravidity
Primigravidae 47 (38.6%) 56 (40.9%)
Secundigravidae 33 (27.0%) 35 (25.5%)
Multigravidae 42 (34.4%) 46 (33.6%)
Mean PCV(%) 32.3 ±3.7% 32.4 ±3.7%
PCV < 33% 29 (23.8%) 29 (21.2%)
PCV ≥ 33% 93 (76.2%) 108 (78.8%)
Arm A: standard 2-Dose IPTp-SP; Arm B: monthly IPTp-SP.
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Figure 1: Parasite clearance in the monthly and 2-dose IPTp-SP
groups. Fisher Exact P = 0.625.
parasitaemia. This is suggestive of the eﬀectiveness of SP
in preventing malaria infection among pregnant women
in Lagos despite reports of high parasitological failure rate
of SP, 24.4% reported in children in southwest Nigeria
[27]. The diﬀerence in response to treatment with SP in
children and pregnant women can be explained by the
report that parasitological response is signiﬁcantly better in
pregnant women than in children treated with same drug
[31]. The reasons for the high eﬃcacy in pregnant women
can be attributed to the presence of acquired immunity
which assists the drug in clearing malaria parasites as well
as providing a prophylactic eﬀect [27, 32]. Kalanda et al.
[33] reported that pregnant women (all gravidae) responded
better than children to treatment with chloroquine and
sulphadoxine-pyrimethamine. Thus, the greater drug sen-
sitivity in pregnant women probably indicates diﬀerences
in host susceptibility rather than parasite resistance. The
absence of parasitaemia after M1 in monthly IPTp-SP and
M2 in the standard 2-dose IPTp-SP agrees with the ﬁndings
of other investigators that the administration of at least
two therapeutic doses of IPTp-SP after the ﬁrst trimester is
eﬀective in preventing maternal and placental malaria as well
as improving pregnancy outcomes among parturient women
as reported in Kenya [34, 35].
The low parasitaemia and the clearance observed during
follow-up months among women who were parasitaemic
at M0, and in women who became parasitaemic after the
ﬁrst dose of SP, suggest that SP, in addition to other factors
such as existing maternal immunity could have provided a
suppressive eﬀect on parasite multiplication.
The proportion of women who became parasitaemic
during the follow-up visits for monthly monitoring of
parasitaemia 2 (1.5%) and 3 (2.5%) in the monthly and the
standard 2-dose IPTp-SP groups, respectively, were similar
at Month 1 (P = 0.445). The only pregnant woman that
had parasitaemia at Month 2 did not receive SP on Month
1. Nevertheless, on administration of a therapeutic dose of
SP, this parasitaemia cleared at the next month’s visit. This
ﬁnding may suggest that the level of SP in the blood was
not able to prevent the multiplication of the parasites. In the
presence of drug resistance, the drug level needed to either
suppressorpreventinfectionisincreased[32].Ofthewomen
studied,only11%ofthemsleptunderinsecticidetreatednet.
Based on parasitaemia, the monthly dosing was not
signiﬁcantly superior than the 2-dose regimen (P> 0.05).
The low number of infected patients in the study may not,
however, permit a more conclusive statement. However, sim-
ilar ﬁnding by Hamer and colleagues [26] indicated that the
monthly dosing was not more eﬃcacious than the standard
2-dose regimen in an area where malaria transmission is
mesoendemic.Contrarily,Fillerandcoworkers[25]r eport ed
that monthly IPTp-SP was a better option than 2-dose IPTp-
SPinareashyperendemicformalaria.Therefore,considering
the 7.7% prevalence of malaria in pregnancy in this study,
Lagos currently appears to be mesoendemic for malaria.
The outcome of the pregnancy was assessed based on
two criteria: (a) if the pregnancy resulted in the birth of a
live baby or not and (b) the birth weight of the live baby.
In this study, though the proportion of deaths was higher
in the 2-dose IPTp-SP than in the monthly IPTp-SP, 3, the
diﬀerence was not statistically signiﬁcant and was not likely
to have been diﬀerentially inﬂuenced by any of the dosing
regimens. The eﬀect of the diﬀerent dosing regimens on low
birth weight was similar (P = 0.581) and consistent with the
r e p o r t si nZ a m b i ab yG i l la n dc o - w o r k e r s[ 36]a n dH a m e r
and colleagues [26].
Of the 12 women assessed for placental parasitaemia in
the monthly IPTp-SP arm, none (0) had malaria parasites.
However,theunwillingnessofthewomentopermitplacental
biopsies (though they agreed at enrolment) and their
deliveries at other health facilities limits the interpretation of
the data obtained from the placental samples in this study.
In conclusion, Sulphadoxine-pyrimethamine could be
said to be eﬀective in protecting pregnant women against
malaria infection in Lagos using the limited data available
in the light of heightened fears of resistance and threatened
eﬃcacy when used as IPTp. Monthly IPTp-SP could be said
tobeequivalenttothestandard2-doseregimeninprotecting
pregnant women against malaria infection and in the birth
outcome.Malaria Research and Treatment 5
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